Xintela recruits Jeffrey Abbey to Targinta

Lund, Sweden, 14 December 2020 –Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of innovative oncology therapies.  

Previously, Mr. Abbey was chief executive officer of Argos Therapeutics, an immuno-oncology company which he led from early-stage development through completion of a phase 3 trial, raised over $250 million in equity financing, including an initial public offering on US Nasdaq, and built to an organization of 140 people. Prior to becoming chief executive officer, Mr. Abbey was chief business officer at Argos and was responsible for completing numerous deals with major biopharmaceutical companies resulting in the receipt of over $100 million of non-dilutive capital. Mr. Abbey has an M.B.A and J.D. from the University of Virginia and a B.S. in Mathematics and Economics from Brown University.

“I am excited to join Evy Lundgren-Åkerlund and the Targinta team in building a mission-driven and results-oriented biotechnology company focused on bringing new treatments to patients with aggressive, difficult to treat solid tumors. I believe that Targinta’s cutting-edge science will lead to a pipeline of programs that can transform how cancer is treated.  I welcome the opportunity to contribute towards fostering the company’s further development,” says Jeffrey Abbey.

“This is very positive for our subsidiary Targinta and I am really pleased to have Jeffrey Abbey in our team. He will join Targinta immediately and will have a leading role in the Targinta management team working on financing and building the organization, product development and industry partnering,” says Xintelas CEO Evy Lundgren-Åkerlund.

Xintela AB (publ)
‍Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
E-post: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela
‍Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela’s Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Download the press release (PDF) here.

‍